All In Biotech

Drug Trial Radar · NCT04870333

PROphylaxis for paTiEnts at Risk of COVID-19 infecTion -V

PROphylaxis for paTiEnts at Risk of COVID-19 infecTion

Last checked: Nov 19, 2026Latest source record: Jun 20, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 2,240 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

2,240

Actual

Start

Feb 19, 2021

Primary completion

Apr 16, 2025

Study completion Apr 16, 2025

Sponsor

Lead sponsor
Cambridge University Hospitals NHS Foundation TrustAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Life Arc; Kidney Research UK (KRUK); UNION therapeutics; Addenbrookes Charitable Trust; GlaxoSmithKline; National Institute for Health Research, United Kingdom
First posted
May 3, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Prevention
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

COVID-19 (SARS-CoV2 virus) was declared a global pandemic by the WHO on 11th March 2020. Currently there are no drugs proven to prevent COVID-19 or to reduce the severity of illness if given as prophylaxis. Although vaccines are now available, there remains a need for other prophylactic agents until vaccine use becomes widespread globally and effectiveness and durability is established, particularly in immunocompromised individuals, for whom vaccine responses may be suboptimal. Efforts are underway to repurpose established drugs with well understood drug interactions and safety profiles. PROTECT-V is a platform trial to test prophylactic interventions against SARS-CoV2 infection in vulnerable patient populations at particularly high risk of COVID-19 and its complications, seeking to identify treatments that either might prevent the disease from occurring or may reduce the number of cases where the disease becomes serious or life-threatening. In PROTECT-V, multiple agents can be evaluated on the same platform across vulnerable populations, with the option of adding additional treatments at later time points as these become available. The expectation is for as many sites as possible to recruit to all available trial treatments at any time, however, the platform structure and randomisation/data collection systems allow sites to open the trial treatment arms according to their capacity. The trial opened with intranasal niclosamide and matched placebo, aiming to recruit 1500 vulnerable renal patients in February 2021. A parallel study protocol, was conducted in India, sponsored by The George Institute. Recruitment of around 750 Indian patients was completed in with the rest of the study arm recruitment in November 2022. The Niclosamide arm of the study was completed in June 2023. The second agent, intranasal and inhaled ciclesonide and matched placebo, was meant to be added to the platform in mid-2022 in the same renal patient population however it was unable to be included due to other factor. Sotrovimab and matched placebo have been added to the platform in August 2022 which aim to recruit approximately 800-1000 patients from the main study population with additional patient groups with primary immunodeficiency, any Haematology or Oncology patient who is currently receiving or has received chemotherapy or who is immunocompromised as a result of their disease or treatment, those with a diagnosis of an autoimmune or inflammatory disease receiving immunosuppression and also haematopoietic stem cell transplant recipients.

Conditions

  • Covid19

Interventions

  • NiclosamideDrug

    140μL of a 1% niclosamide ethanolamine solution in each nostril twice daily, equivalent to 1.4mg of niclosamide ethanolamine salt per nostril twice daily, approximately 12 hours apart. Total daily dose 5.6mg niclosamide ethanolamine salt (4.7mg free niclosamide acid). Treatment duration will be 6-9 months or up to 28 days after COVID-19 diagnosis unless hospitalised. Participants hospitalised with a diagnosis of COVID-19 should stop the randomised treatment immediately.

  • PlaceboDrug

    140μL of a matching placebo solution in each nostril twice daily. Treatment duration will be 6-9 months or up to 28 days after COVID-19 diagnosis unless hospitalised. Participants hospitalised with a diagnosis of COVID-19 should stop the randomised treatment immediately.

  • CiclesonideDrug

    Participants will be prescribed ciclesonide once daily, administered as follows: Two puffs (320 μg) inhaled via mouth sequentially One puff (160 μg) inhaled via nose Treatment duration will be 6-9 months or up to 28 days after COVID-19 diagnosis unless hospitalised. Participants hospitalised with a diagnosis of COVID-19 should stop the randomised treatment immediately.

  • PlaceboDrug

    Matched placebo: two puffs inhaled via mouth sequentially and one puff inhaled via nose. Treatment duration will be 6-9 months or up to 28 days after COVID-19 diagnosis unless hospitalised. Participants hospitalised with a diagnosis of COVID-19 should stop the randomised treatment immediately.

  • SotrovimabDrug

    There will be a single infusion of sotrovimab administered at the beginning of the study. 500mg of sotrovimab solution (8mL) will be diluted in 42mL of 0.9% sodium chloride and administered by intravenous infusion. 50mLs to be infused over 30 minutes with a 0.2 micrometre inline filter. Four vials will be required for a 2000 mg dose.

  • PlaceboDrug

    There will be a single infusion placebo, in the form of 100mL 0.9% sodium chloride, administered at the beginning of the study.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Confirmed symptomatic COVID-19 infection during treatmentTime frame: 6-9 months. Reported at 24 weeks for niclosamide and ciclesonide arms and 12 weeks for sotrovimab arm from date of IMP administration.

Locations

45 sites in 1 country. Site status is shown where the registry gives one.

  • NHS Lanarkshire - University Hospital Monklands

    Airdrie, United Kingdom

  • University Hospitals Birmingham NHS Foundation Trust

    Birmingham, United Kingdom

  • Betsi Cadwaladr University Health Board

    Bodelwyddan, United Kingdom

  • Brighton and Sussex University Hospitals NHS Trust

    Brighton, United Kingdom

  • North Bristol NHS Trust

    Bristol, United Kingdom

  • West Suffolk NHS Foundation Trust

    Bury St Edmunds, United Kingdom

  • Royal Papworth Hospital NHS Foundation Trust

    Cambridge, United Kingdom

  • East Kent Hospitals University NHS Foundation Trust

    Canterbury, United Kingdom

  • Cardiff & Vale University Health Board

    Cardiff, United Kingdom

  • Epsom and St Helier University Hospitals NHS Trust

    Carshalton, United Kingdom

  • Ayrshire & Arran NHS Trust

    Crosshouse, United Kingdom

  • Dartford and Gravesham NHS Trust

    Dartford, United Kingdom

  • University Hospitals of Derby and Burton NHS Trust

    Derby, United Kingdom

  • Dorset County Hospital NHS Foundation Trust

    Dorchester, United Kingdom

  • NHS Tayside

    Dundee, United Kingdom

  • The Royal Devon and Exeter NHS Foundation Trust

    Exeter, United Kingdom

  • James Paget University Hospital NHS Foundation Trust

    Great Yarmouth, United Kingdom

  • Hull University Teaching Hospitals NHS Trust

    Hull, United Kingdom

  • Queen Elizabeth Hospital, King's Lynn, NHS Foundation Trust

    Kings Lynn, United Kingdom

  • Leeds Teaching Hospitals NHS Trust

    Leeds, United Kingdom

  • University Hospitals of Leicester NHS Trust

    Leicester, United Kingdom

  • Royal Liverpool and Broadgreen University Hospitals NHS Trust

    Liverpool, United Kingdom

  • Barts Health NHS Trust

    London, United Kingdom

  • Guy's and St Thomas' NHS Foundation Trust

    London, United Kingdom

  • Imperial College Healthcare NHS Trust

    London, United Kingdom

  • King's College Hospital NHS Foundation Trust

    London, United Kingdom

  • Royal Free NHS Foundation Trust

    London, United Kingdom

  • St George's University Hospitals NHS Foundation Trust

    London, United Kingdom

  • Manchester University NHS Foundation Trust

    Manchester, United Kingdom

  • Wirral University Teaching Hospital NHS Foundation Trust

    Metropolitan Borough of Wirral, United Kingdom

  • South Tees Hospitals NHS Foundation Trust

    Middlesbrough, United Kingdom

  • Nottingham University Hospitals NHS Trust

    Nottingham, United Kingdom

  • Oxford University Hospitals NHS Foundation Trust

    Oxford, United Kingdom

  • North West Anglia NHS Foundation Trust

    Peterborough, United Kingdom

  • University Hospitals Plymouth NHS Trust

    Plymouth, United Kingdom

  • Portsmouth Hospitals NHS Trust

    Portsmouth, United Kingdom

  • Royal Berkshire NHS Foundation

    Reading, United Kingdom

  • Salford Royal NHS Foundation

    Salford, United Kingdom

  • Sheffield Teaching Hospitals NHS Foundation Trust

    Sheffield, United Kingdom

  • The Shrewsbury and Telford Hospital NHS Trust

    Shrewsbury, United Kingdom

Showing 40 of 45 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.